stockrow
Friday 6 November 2026
Export CGTX’s income statement to Excel — free account
Cognition Therapeutics, Inc.
CGTX Healthcare Biotechnology
- EPS
- +63.6%
- Free cash flow
- +45.4%
Quarter to June 2026, against a year earlier
0.69
0.05
+7.81%
Follow CGTX
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(109.73%) | (88.60%) | (92.82%) | (83.76%) | |
| (78.86%) | (59.75%) | (65.65%) | (57.33%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(76.91%) | (68.76%) | (65.61%) | (50.93%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.38) | (0.34) | (0.23) | (0.20) | |
Free Cash Flow |
(29.53) | (24.58) | (20.25) | (17.69) | |
Capital Expenditures |
— | 0.01 | — | (0.01) | |
| Other line items | |||||
Cash ROIC |
(38.68%) | (34.49%) | (33.13%) | (26.10%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | (1,911.96) | (2,380.06) | (2,287.56) | |
Operating CF/Net income |
1.06 | 1.05 | 1.03 | 1.05 | |
Depreciation/Fixed assets |
1.50 | 2.45 | 3.26 | 2.82 | |
Capex/Depreciation |
0.00 | 0.02 | 0.00 | (0.05) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.38) | (0.34) | (0.23) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | — | 0.00 |
Columns are period end dates · fundamentals updated 25 Oct 2026